| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Middle Aged | 263 | 2024 | 7836 | 3.420 |
Why?
|
| Female | 330 | 2025 | 12396 | 3.350 |
Why?
|
| Diabetes, Gestational | 32 | 2025 | 311 | 3.270 |
Why?
|
| Humans | 371 | 2025 | 17314 | 3.100 |
Why?
|
| Adult | 239 | 2025 | 7500 | 3.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 35 | 2019 | 664 | 3.040 |
Why?
|
| Breast Neoplasms | 44 | 2017 | 969 | 2.870 |
Why?
|
| HIV Infections | 37 | 2019 | 712 | 2.860 |
Why?
|
| Aged | 187 | 2024 | 6084 | 2.590 |
Why?
|
| Male | 231 | 2025 | 9804 | 2.530 |
Why?
|
| Risk Factors | 155 | 2025 | 3258 | 2.460 |
Why?
|
| California | 127 | 2025 | 2311 | 2.460 |
Why?
|
| Skin Neoplasms | 9 | 2020 | 58 | 2.260 |
Why?
|
| Breast Feeding | 12 | 2025 | 113 | 1.940 |
Why?
|
| Cohort Studies | 104 | 2022 | 2514 | 1.870 |
Why?
|
| Risk Assessment | 34 | 2020 | 1076 | 1.650 |
Why?
|
| Carcinoma, Basal Cell | 7 | 2020 | 24 | 1.630 |
Why?
|
| Incidence | 63 | 2020 | 1266 | 1.620 |
Why?
|
| Obesity | 32 | 2025 | 814 | 1.610 |
Why?
|
| Ethnic Groups | 21 | 2016 | 451 | 1.600 |
Why?
|
| Follow-Up Studies | 54 | 2024 | 1151 | 1.520 |
Why?
|
| Young Adult | 56 | 2025 | 2465 | 1.490 |
Why?
|
| Pregnancy | 57 | 2025 | 1463 | 1.460 |
Why?
|
| Antiretroviral Therapy, Highly Active | 10 | 2016 | 91 | 1.430 |
Why?
|
| Case-Control Studies | 74 | 2016 | 1098 | 1.420 |
Why?
|
| Patient Compliance | 12 | 2021 | 277 | 1.390 |
Why?
|
| Adolescent | 74 | 2024 | 3538 | 1.370 |
Why?
|
| Body Mass Index | 47 | 2025 | 937 | 1.370 |
Why?
|
| Aged, 80 and over | 64 | 2017 | 1925 | 1.350 |
Why?
|
| European Continental Ancestry Group | 26 | 2018 | 476 | 1.340 |
Why?
|
| Retrospective Studies | 59 | 2024 | 2415 | 1.320 |
Why?
|
| Prospective Studies | 52 | 2025 | 1226 | 1.320 |
Why?
|
| Health Maintenance Organizations | 27 | 2013 | 407 | 1.290 |
Why?
|
| Diabetes Mellitus | 12 | 2017 | 452 | 1.280 |
Why?
|
| Lactation | 9 | 2018 | 34 | 1.280 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2024 | 243 | 1.270 |
Why?
|
| Neoplasms | 21 | 2019 | 446 | 1.250 |
Why?
|
| Weight Gain | 13 | 2018 | 156 | 1.250 |
Why?
|
| Continental Population Groups | 20 | 2019 | 286 | 1.220 |
Why?
|
| Myocardial Infarction | 17 | 2016 | 224 | 1.180 |
Why?
|
| Anti-HIV Agents | 12 | 2016 | 159 | 1.170 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2020 | 56 | 1.140 |
Why?
|
| Lung Neoplasms | 15 | 2021 | 268 | 1.070 |
Why?
|
| Exercise | 18 | 2024 | 515 | 1.050 |
Why?
|
| Hispanic Americans | 21 | 2018 | 375 | 1.030 |
Why?
|
| Prostatic Neoplasms | 17 | 2017 | 263 | 0.990 |
Why?
|
| Biomarkers, Tumor | 9 | 2017 | 145 | 0.990 |
Why?
|
| Prenatal Exposure Delayed Effects | 8 | 2025 | 168 | 0.960 |
Why?
|
| Adenoma | 5 | 2016 | 95 | 0.960 |
Why?
|
| Risk | 27 | 2015 | 496 | 0.960 |
Why?
|
| African Americans | 23 | 2017 | 439 | 0.950 |
Why?
|
| African Continental Ancestry Group | 12 | 2018 | 144 | 0.910 |
Why?
|
| Blood Glucose | 20 | 2015 | 314 | 0.900 |
Why?
|
| Colorectal Neoplasms | 9 | 2016 | 622 | 0.870 |
Why?
|
| Motor Activity | 9 | 2014 | 208 | 0.870 |
Why?
|
| Longitudinal Studies | 34 | 2019 | 674 | 0.860 |
Why?
|
| Proportional Hazards Models | 39 | 2019 | 701 | 0.860 |
Why?
|
| Hypoglycemic Agents | 12 | 2015 | 250 | 0.850 |
Why?
|
| Treatment Outcome | 26 | 2024 | 1160 | 0.840 |
Why?
|
| Odds Ratio | 41 | 2016 | 640 | 0.840 |
Why?
|
| Registries | 21 | 2017 | 460 | 0.840 |
Why?
|
| Age Factors | 31 | 2021 | 878 | 0.830 |
Why?
|
| Smoking | 24 | 2016 | 429 | 0.830 |
Why?
|
| Postpartum Period | 6 | 2024 | 79 | 0.820 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 7 | 2015 | 42 | 0.810 |
Why?
|
| Time Factors | 34 | 2018 | 1039 | 0.810 |
Why?
|
| Hypertension | 12 | 2019 | 469 | 0.800 |
Why?
|
| Surveys and Questionnaires | 32 | 2019 | 1282 | 0.800 |
Why?
|
| Health Status | 8 | 2018 | 293 | 0.760 |
Why?
|
| Barrett Esophagus | 11 | 2013 | 114 | 0.750 |
Why?
|
| Cardiovascular Diseases | 14 | 2016 | 532 | 0.750 |
Why?
|
| Dementia | 9 | 2019 | 121 | 0.740 |
Why?
|
| Life Style | 16 | 2019 | 316 | 0.720 |
Why?
|
| Melanoma | 3 | 2020 | 35 | 0.710 |
Why?
|
| Aging | 10 | 2015 | 160 | 0.710 |
Why?
|
| Puberty | 5 | 2024 | 58 | 0.700 |
Why?
|
| Estrogen Replacement Therapy | 10 | 2010 | 100 | 0.690 |
Why?
|
| Calcineurin Inhibitors | 1 | 2020 | 2 | 0.690 |
Why?
|
| United States | 39 | 2019 | 3866 | 0.690 |
Why?
|
| Glucocorticoids | 1 | 2020 | 23 | 0.680 |
Why?
|
| Antiviral Agents | 3 | 2019 | 99 | 0.670 |
Why?
|
| Dermatitis, Atopic | 1 | 2020 | 16 | 0.670 |
Why?
|
| Weight Loss | 4 | 2015 | 294 | 0.660 |
Why?
|
| Delivery of Health Care, Integrated | 7 | 2019 | 535 | 0.660 |
Why?
|
| Logistic Models | 28 | 2021 | 879 | 0.640 |
Why?
|
| SEER Program | 6 | 2017 | 92 | 0.640 |
Why?
|
| Patient Satisfaction | 6 | 2006 | 191 | 0.630 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2015 | 51 | 0.620 |
Why?
|
| Sex Factors | 20 | 2021 | 603 | 0.610 |
Why?
|
| Health Promotion | 5 | 2019 | 279 | 0.610 |
Why?
|
| Hypoglycemia | 5 | 2017 | 46 | 0.590 |
Why?
|
| Multivariate Analysis | 23 | 2021 | 535 | 0.580 |
Why?
|
| Health Status Disparities | 5 | 2017 | 149 | 0.560 |
Why?
|
| Prognosis | 20 | 2017 | 603 | 0.550 |
Why?
|
| Insulin | 12 | 2013 | 188 | 0.550 |
Why?
|
| Lithium | 1 | 2017 | 1 | 0.550 |
Why?
|
| Educational Status | 10 | 2019 | 177 | 0.550 |
Why?
|
| Fractures, Bone | 8 | 2005 | 92 | 0.540 |
Why?
|
| Diabetes Complications | 9 | 2015 | 105 | 0.540 |
Why?
|
| Urinary Bladder Neoplasms | 5 | 2024 | 57 | 0.530 |
Why?
|
| CD4 Lymphocyte Count | 15 | 2017 | 181 | 0.530 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2015 | 52 | 0.530 |
Why?
|
| Lymph Nodes | 2 | 2016 | 17 | 0.520 |
Why?
|
| Cross-Sectional Studies | 21 | 2025 | 1280 | 0.520 |
Why?
|
| Pregnancy Complications | 6 | 2025 | 197 | 0.520 |
Why?
|
| Gene Expression Profiling | 4 | 2017 | 35 | 0.520 |
Why?
|
| Homeodomain Proteins | 2 | 2015 | 16 | 0.520 |
Why?
|
| Thiazolidinediones | 7 | 2015 | 50 | 0.520 |
Why?
|
| Insulin Resistance | 9 | 2014 | 128 | 0.510 |
Why?
|
| Delivery of Health Care | 5 | 2021 | 390 | 0.510 |
Why?
|
| Prevalence | 13 | 2017 | 840 | 0.500 |
Why?
|
| Insurance, Health | 5 | 2019 | 170 | 0.500 |
Why?
|
| Physicians, Family | 4 | 2000 | 36 | 0.500 |
Why?
|
| Lower Urinary Tract Symptoms | 2 | 2013 | 13 | 0.490 |
Why?
|
| Estrogens | 6 | 2012 | 60 | 0.480 |
Why?
|
| Coronary Artery Disease | 5 | 2017 | 112 | 0.480 |
Why?
|
| Overweight | 4 | 2016 | 266 | 0.480 |
Why?
|
| Restless Legs Syndrome | 1 | 2015 | 4 | 0.480 |
Why?
|
| Infant Formula | 1 | 2015 | 9 | 0.480 |
Why?
|
| Behavior Therapy | 2 | 2015 | 126 | 0.460 |
Why?
|
| Child Development | 1 | 2015 | 53 | 0.460 |
Why?
|
| Asthma | 9 | 2009 | 400 | 0.450 |
Why?
|
| Hospitalization | 17 | 2016 | 804 | 0.450 |
Why?
|
| Child | 21 | 2025 | 2403 | 0.440 |
Why?
|
| Mammography | 9 | 2012 | 168 | 0.430 |
Why?
|
| Asian Americans | 7 | 2017 | 163 | 0.420 |
Why?
|
| Diet | 8 | 2024 | 355 | 0.420 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2015 | 372 | 0.420 |
Why?
|
| Hepatitis C, Chronic | 2 | 2013 | 74 | 0.420 |
Why?
|
| Drug Costs | 1 | 2013 | 32 | 0.410 |
Why?
|
| Managed Care Programs | 11 | 2017 | 300 | 0.410 |
Why?
|
| Health Resources | 1 | 2013 | 34 | 0.410 |
Why?
|
| Proton Pump Inhibitors | 2 | 2011 | 24 | 0.410 |
Why?
|
| Receptors, Interleukin | 1 | 2013 | 4 | 0.410 |
Why?
|
| Substance-Related Disorders | 5 | 2013 | 425 | 0.410 |
Why?
|
| Viral Load | 9 | 2017 | 136 | 0.400 |
Why?
|
| Carcinoma in Situ | 2 | 2009 | 17 | 0.400 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2010 | 302 | 0.400 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2017 | 63 | 0.390 |
Why?
|
| Hepatitis C | 3 | 2019 | 65 | 0.390 |
Why?
|
| Colon | 1 | 2012 | 20 | 0.390 |
Why?
|
| Magnetic Fields | 1 | 2012 | 6 | 0.390 |
Why?
|
| Age Distribution | 14 | 2017 | 239 | 0.380 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2017 | 118 | 0.380 |
Why?
|
| Schizophrenia | 6 | 2012 | 76 | 0.380 |
Why?
|
| Drug Utilization Review | 3 | 2007 | 23 | 0.380 |
Why?
|
| Coronary Disease | 7 | 2017 | 146 | 0.380 |
Why?
|
| Pediatric Obesity | 2 | 2025 | 88 | 0.380 |
Why?
|
| Prehypertension | 1 | 2012 | 21 | 0.380 |
Why?
|
| Cell Phone | 1 | 2012 | 9 | 0.380 |
Why?
|
| Mental Recall | 1 | 2012 | 29 | 0.380 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2009 | 165 | 0.370 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2013 | 381 | 0.370 |
Why?
|
| Inflammation | 1 | 2012 | 63 | 0.370 |
Why?
|
| Adipose Tissue | 7 | 2015 | 65 | 0.370 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2012 | 39 | 0.370 |
Why?
|
| Body Constitution | 7 | 2007 | 39 | 0.360 |
Why?
|
| Stroke | 7 | 2016 | 309 | 0.360 |
Why?
|
| Infant, Newborn | 14 | 2025 | 805 | 0.360 |
Why?
|
| Hip Fractures | 2 | 2010 | 71 | 0.360 |
Why?
|
| Gastroesophageal Reflux | 9 | 2014 | 77 | 0.360 |
Why?
|
| Neoplasm Staging | 15 | 2017 | 338 | 0.350 |
Why?
|
| Menopause | 3 | 2007 | 68 | 0.350 |
Why?
|
| Health | 3 | 2015 | 32 | 0.350 |
Why?
|
| Health Behavior | 7 | 2015 | 346 | 0.350 |
Why?
|
| Health Services | 4 | 2013 | 110 | 0.340 |
Why?
|
| Body Weight | 9 | 2018 | 203 | 0.340 |
Why?
|
| Risk Reduction Behavior | 5 | 2019 | 104 | 0.340 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2017 | 27 | 0.340 |
Why?
|
| Primary Health Care | 6 | 2021 | 726 | 0.330 |
Why?
|
| Social Class | 5 | 2013 | 116 | 0.330 |
Why?
|
| Body Composition | 5 | 2013 | 91 | 0.330 |
Why?
|
| Depression | 5 | 2025 | 486 | 0.330 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 31 | 0.330 |
Why?
|
| Physicians, Women | 2 | 2000 | 10 | 0.330 |
Why?
|
| Histamine H2 Antagonists | 1 | 2010 | 13 | 0.330 |
Why?
|
| Socioeconomic Factors | 14 | 2019 | 605 | 0.330 |
Why?
|
| Infant | 14 | 2025 | 1161 | 0.330 |
Why?
|
| Genome-Wide Association Study | 5 | 2015 | 248 | 0.330 |
Why?
|
| Parity | 10 | 2010 | 57 | 0.320 |
Why?
|
| Postmenopause | 8 | 2017 | 248 | 0.320 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2016 | 363 | 0.320 |
Why?
|
| Women | 2 | 1999 | 12 | 0.310 |
Why?
|
| Spouses | 2 | 1999 | 9 | 0.310 |
Why?
|
| Dyslipidemias | 3 | 2016 | 56 | 0.300 |
Why?
|
| Receptors, Estrogen | 5 | 2016 | 53 | 0.300 |
Why?
|
| Stress, Psychological | 3 | 2019 | 134 | 0.300 |
Why?
|
| Adenocarcinoma | 7 | 2013 | 173 | 0.300 |
Why?
|
| Colonoscopy | 5 | 2016 | 257 | 0.290 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2017 | 65 | 0.290 |
Why?
|
| Survivors | 6 | 2017 | 157 | 0.290 |
Why?
|
| Lipids | 3 | 2016 | 69 | 0.280 |
Why?
|
| Esophageal Neoplasms | 6 | 2013 | 115 | 0.280 |
Why?
|
| Disease Progression | 6 | 2020 | 259 | 0.280 |
Why?
|
| Genomics | 3 | 2017 | 56 | 0.280 |
Why?
|
| Progestins | 4 | 2004 | 25 | 0.280 |
Why?
|
| Child, Preschool | 12 | 2024 | 1380 | 0.280 |
Why?
|
| Receptor, ErbB-2 | 5 | 2015 | 47 | 0.270 |
Why?
|
| Anthropometry | 7 | 2015 | 60 | 0.270 |
Why?
|
| Neoplasm Invasiveness | 7 | 2024 | 79 | 0.270 |
Why?
|
| Healthcare Disparities | 4 | 2018 | 202 | 0.270 |
Why?
|
| Coinfection | 2 | 2019 | 31 | 0.270 |
Why?
|
| Osteoporosis | 4 | 2017 | 74 | 0.270 |
Why?
|
| Pharmacists | 1 | 2007 | 48 | 0.260 |
Why?
|
| Medication Adherence | 2 | 2010 | 235 | 0.260 |
Why?
|
| Health Services Accessibility | 7 | 2016 | 271 | 0.260 |
Why?
|
| Confidence Intervals | 13 | 2015 | 231 | 0.260 |
Why?
|
| Analysis of Variance | 8 | 2018 | 139 | 0.250 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2006 | 11 | 0.250 |
Why?
|
| Aromatase Inhibitors | 2 | 2017 | 33 | 0.250 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2006 | 12 | 0.250 |
Why?
|
| Contraceptives, Oral | 4 | 1998 | 25 | 0.250 |
Why?
|
| HIV-1 | 6 | 2012 | 71 | 0.250 |
Why?
|
| Antipsychotic Agents | 3 | 2011 | 49 | 0.250 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2017 | 18 | 0.250 |
Why?
|
| Linear Models | 11 | 2016 | 206 | 0.240 |
Why?
|
| Health Services Research | 7 | 2014 | 202 | 0.240 |
Why?
|
| Predictive Value of Tests | 8 | 2017 | 342 | 0.240 |
Why?
|
| Comorbidity | 10 | 2015 | 560 | 0.240 |
Why?
|
| Metabolic Syndrome | 3 | 2010 | 65 | 0.240 |
Why?
|
| Computational Biology | 2 | 2015 | 26 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2008 | 367 | 0.230 |
Why?
|
| Cause of Death | 6 | 2017 | 176 | 0.230 |
Why?
|
| Quality of Life | 7 | 2019 | 499 | 0.230 |
Why?
|
| Sex Distribution | 8 | 2017 | 180 | 0.230 |
Why?
|
| Heart Failure | 5 | 2017 | 401 | 0.230 |
Why?
|
| Marijuana Smoking | 2 | 2003 | 52 | 0.230 |
Why?
|
| Ambulatory Care | 8 | 2013 | 225 | 0.230 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2004 | 5 | 0.220 |
Why?
|
| Staphylococcal Infections | 2 | 2015 | 16 | 0.220 |
Why?
|
| Cystitis | 1 | 2004 | 2 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 52 | 0.220 |
Why?
|
| Mitomycin | 1 | 2024 | 4 | 0.220 |
Why?
|
| Isothiocyanates | 1 | 2024 | 8 | 0.220 |
Why?
|
| BCG Vaccine | 1 | 2024 | 8 | 0.220 |
Why?
|
| Remote Consultation | 1 | 2004 | 9 | 0.220 |
Why?
|
| Survival Rate | 5 | 2017 | 252 | 0.220 |
Why?
|
| Quality of Health Care | 4 | 2004 | 259 | 0.220 |
Why?
|
| Depression, Postpartum | 1 | 2024 | 22 | 0.220 |
Why?
|
| Venous Thrombosis | 1 | 2004 | 21 | 0.220 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2009 | 109 | 0.220 |
Why?
|
| Clinical Protocols | 1 | 2004 | 40 | 0.220 |
Why?
|
| Hepacivirus | 3 | 2019 | 52 | 0.220 |
Why?
|
| Receptors, Progesterone | 5 | 2015 | 50 | 0.220 |
Why?
|
| Mental Disorders | 3 | 2013 | 274 | 0.220 |
Why?
|
| Menarche | 2 | 2022 | 28 | 0.210 |
Why?
|
| Research Design | 3 | 2015 | 336 | 0.210 |
Why?
|
| Asian Continental Ancestry Group | 5 | 2016 | 87 | 0.210 |
Why?
|
| Adiponectin | 2 | 2014 | 21 | 0.210 |
Why?
|
| Bone Density | 3 | 2017 | 94 | 0.210 |
Why?
|
| Appointments and Schedules | 2 | 2013 | 25 | 0.210 |
Why?
|
| Telemedicine | 2 | 2024 | 181 | 0.210 |
Why?
|
| Pregnancy Outcome | 4 | 2009 | 158 | 0.210 |
Why?
|
| Pneumonia | 2 | 2017 | 49 | 0.210 |
Why?
|
| Glucose Intolerance | 2 | 2015 | 43 | 0.200 |
Why?
|
| Women's Health | 7 | 2010 | 197 | 0.200 |
Why?
|
| Epidemiology | 1 | 2003 | 6 | 0.200 |
Why?
|
| Self Report | 4 | 2019 | 257 | 0.200 |
Why?
|
| Vitamin D | 2 | 2017 | 73 | 0.200 |
Why?
|
| Violence | 1 | 2003 | 33 | 0.200 |
Why?
|
| Physician-Patient Relations | 3 | 2000 | 163 | 0.200 |
Why?
|
| Language | 2 | 2015 | 49 | 0.200 |
Why?
|
| Genetic Variation | 1 | 2003 | 77 | 0.200 |
Why?
|
| Specialization | 2 | 1999 | 21 | 0.190 |
Why?
|
| Foot Diseases | 1 | 2002 | 1 | 0.190 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2002 | 4 | 0.190 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2007 | 37 | 0.190 |
Why?
|
| Chronic Disease | 3 | 2009 | 397 | 0.190 |
Why?
|
| Diabetic Angiopathies | 3 | 2007 | 31 | 0.190 |
Why?
|
| Choice Behavior | 2 | 1999 | 45 | 0.190 |
Why?
|
| Regression Analysis | 12 | 2012 | 270 | 0.190 |
Why?
|
| Psychotic Disorders | 3 | 2011 | 49 | 0.190 |
Why?
|
| Exercise Test | 3 | 2017 | 45 | 0.190 |
Why?
|
| Glucose Tolerance Test | 6 | 2014 | 107 | 0.190 |
Why?
|
| Electronic Mail | 3 | 2019 | 51 | 0.190 |
Why?
|
| Drug Therapy, Combination | 6 | 2013 | 107 | 0.180 |
Why?
|
| Early Detection of Cancer | 6 | 2021 | 529 | 0.180 |
Why?
|
| Albuminuria | 1 | 2011 | 35 | 0.180 |
Why?
|
| Adult Children | 2 | 2012 | 8 | 0.180 |
Why?
|
| Prostatectomy | 3 | 2017 | 75 | 0.180 |
Why?
|
| Attitude to Health | 2 | 1999 | 147 | 0.180 |
Why?
|
| Colonic Neoplasms | 5 | 2008 | 163 | 0.180 |
Why?
|
| Thyroid Neoplasms | 2 | 2019 | 12 | 0.180 |
Why?
|
| Antioxidants | 3 | 2011 | 40 | 0.180 |
Why?
|
| Lipoproteins, LDL | 3 | 2016 | 12 | 0.180 |
Why?
|
| Leukocyte Count | 2 | 2012 | 23 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 3 | 2018 | 81 | 0.180 |
Why?
|
| Prochlorperazine | 1 | 2001 | 1 | 0.180 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2001 | 1 | 0.180 |
Why?
|
| Antiemetics | 1 | 2001 | 3 | 0.180 |
Why?
|
| Mass Screening | 5 | 2008 | 672 | 0.180 |
Why?
|
| Precancerous Conditions | 4 | 2009 | 48 | 0.170 |
Why?
|
| Interviews as Topic | 8 | 2010 | 306 | 0.170 |
Why?
|
| Health Care Costs | 3 | 2002 | 207 | 0.170 |
Why?
|
| Anti-Retroviral Agents | 4 | 2015 | 82 | 0.170 |
Why?
|
| Keratinocytes | 1 | 2020 | 5 | 0.170 |
Why?
|
| Estrogen Receptor alpha | 3 | 2015 | 25 | 0.170 |
Why?
|
| Biomarkers | 5 | 2014 | 307 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2015 | 123 | 0.170 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2020 | 1 | 0.170 |
Why?
|
| Valproic Acid | 1 | 2020 | 3 | 0.170 |
Why?
|
| Patient Selection | 4 | 2015 | 176 | 0.170 |
Why?
|
| Medicine | 2 | 1999 | 18 | 0.160 |
Why?
|
| Glycated Hemoglobin A | 4 | 2010 | 184 | 0.160 |
Why?
|
| Skinfold Thickness | 5 | 2015 | 17 | 0.160 |
Why?
|
| Patient Education as Topic | 4 | 2014 | 193 | 0.160 |
Why?
|
| Metformin | 3 | 2015 | 50 | 0.160 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 96 | 0.160 |
Why?
|
| Alcohol Drinking | 8 | 2014 | 356 | 0.160 |
Why?
|
| Caregivers | 2 | 2019 | 128 | 0.160 |
Why?
|
| Hepatitis B, Chronic | 3 | 2012 | 33 | 0.160 |
Why?
|
| Watchful Waiting | 1 | 2019 | 22 | 0.160 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2021 | 195 | 0.160 |
Why?
|
| Cerebrovascular Disorders | 7 | 2013 | 31 | 0.160 |
Why?
|
| Tamoxifen | 3 | 2009 | 55 | 0.160 |
Why?
|
| Puberty, Precocious | 1 | 2019 | 8 | 0.160 |
Why?
|
| Stroke Rehabilitation | 2 | 2009 | 3 | 0.160 |
Why?
|
| Pilot Projects | 4 | 2014 | 211 | 0.160 |
Why?
|
| Glycemic Index | 2 | 2008 | 19 | 0.160 |
Why?
|
| Rehabilitation Centers | 2 | 2009 | 7 | 0.160 |
Why?
|
| Nurse Practitioners | 1 | 1999 | 20 | 0.160 |
Why?
|
| Shoulder Fractures | 3 | 2004 | 4 | 0.160 |
Why?
|
| Accidental Falls | 5 | 2006 | 46 | 0.160 |
Why?
|
| Immunoenzyme Techniques | 3 | 2014 | 22 | 0.160 |
Why?
|
| Social Values | 1 | 2019 | 14 | 0.160 |
Why?
|
| RNA, Viral | 3 | 2008 | 65 | 0.160 |
Why?
|
| Gynecology | 1 | 1999 | 22 | 0.150 |
Why?
|
| Dementia, Vascular | 2 | 2010 | 4 | 0.150 |
Why?
|
| RNA, Messenger | 3 | 2014 | 72 | 0.150 |
Why?
|
| DNA Repair | 2 | 2008 | 10 | 0.150 |
Why?
|
| Physical Fitness | 2 | 2015 | 70 | 0.150 |
Why?
|
| Prenatal Care | 2 | 2025 | 127 | 0.150 |
Why?
|
| Confounding Factors (Epidemiology) | 7 | 2014 | 84 | 0.150 |
Why?
|
| Medicaid | 5 | 2018 | 189 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 2 | 2006 | 143 | 0.150 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2015 | 4 | 0.150 |
Why?
|
| Mindfulness | 1 | 2019 | 30 | 0.150 |
Why?
|
| Sensitivity and Specificity | 8 | 2016 | 298 | 0.150 |
Why?
|
| Alzheimer Disease | 2 | 2010 | 49 | 0.140 |
Why?
|
| Waist Circumference | 2 | 2015 | 33 | 0.140 |
Why?
|
| Genotyping Techniques | 2 | 2015 | 26 | 0.140 |
Why?
|
| Helicobacter Infections | 2 | 2008 | 22 | 0.140 |
Why?
|
| Helicobacter pylori | 2 | 2008 | 24 | 0.140 |
Why?
|
| Prostate-Specific Antigen | 3 | 2014 | 75 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2011 | 120 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 24 | 0.140 |
Why?
|
| Occult Blood | 3 | 2016 | 155 | 0.140 |
Why?
|
| Reproducibility of Results | 7 | 2015 | 357 | 0.140 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 3 | 2005 | 9 | 0.140 |
Why?
|
| Coronary Vessels | 1 | 2017 | 11 | 0.140 |
Why?
|
| Social Support | 3 | 2012 | 207 | 0.140 |
Why?
|
| Calcium | 1 | 2017 | 30 | 0.140 |
Why?
|
| Vascular Calcification | 1 | 2017 | 8 | 0.140 |
Why?
|
| Transcriptome | 1 | 2017 | 25 | 0.140 |
Why?
|
| HIV Protease Inhibitors | 2 | 2011 | 24 | 0.140 |
Why?
|
| Cholesterol | 4 | 2012 | 82 | 0.140 |
Why?
|
| Prenatal Diagnosis | 1 | 1997 | 17 | 0.140 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2017 | 5 | 0.140 |
Why?
|
| Forecasting | 1 | 2017 | 68 | 0.140 |
Why?
|
| Medical Records | 3 | 2010 | 91 | 0.130 |
Why?
|
| Contraceptive Agents, Female | 2 | 2012 | 12 | 0.130 |
Why?
|
| Cost Sharing | 1 | 2007 | 28 | 0.130 |
Why?
|
| Dietary Fats | 4 | 2009 | 89 | 0.130 |
Why?
|
| Preventive Health Services | 2 | 2003 | 147 | 0.130 |
Why?
|
| Breast Cancer Lymphedema | 1 | 2016 | 4 | 0.130 |
Why?
|
| Neoplasm Grading | 2 | 2014 | 49 | 0.130 |
Why?
|
| Metabolic Equivalent | 1 | 2016 | 8 | 0.130 |
Why?
|
| Life Expectancy | 1 | 2016 | 34 | 0.130 |
Why?
|
| Pneumococcal Infections | 1 | 2016 | 44 | 0.130 |
Why?
|
| Dideoxynucleosides | 1 | 2016 | 8 | 0.130 |
Why?
|
| Survival Analysis | 5 | 2017 | 202 | 0.120 |
Why?
|
| Immunoassay | 1 | 2016 | 9 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2016 | 68 | 0.120 |
Why?
|
| Health Care Surveys | 5 | 2004 | 211 | 0.120 |
Why?
|
| Cost of Illness | 2 | 2012 | 92 | 0.120 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 20 | 0.120 |
Why?
|
| Mutation | 2 | 2008 | 132 | 0.120 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2015 | 3 | 0.120 |
Why?
|
| Staphylococcus aureus | 1 | 2015 | 5 | 0.120 |
Why?
|
| Dietary Fiber | 3 | 2009 | 60 | 0.120 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 437 | 0.120 |
Why?
|
| Exercise Therapy | 1 | 2016 | 72 | 0.120 |
Why?
|
| Sirolimus | 1 | 2015 | 2 | 0.120 |
Why?
|
| Organ Transplantation | 1 | 2015 | 3 | 0.120 |
Why?
|
| Transplant Recipients | 1 | 2015 | 5 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 62 | 0.120 |
Why?
|
| Angina Pectoris | 1 | 2015 | 11 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2015 | 86 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 17 | 0.120 |
Why?
|
| Nomograms | 1 | 2015 | 12 | 0.120 |
Why?
|
| Health Surveys | 5 | 2017 | 245 | 0.120 |
Why?
|
| Telomere | 1 | 2015 | 18 | 0.120 |
Why?
|
| Maternal Exposure | 2 | 2006 | 66 | 0.120 |
Why?
|
| Arteriosclerosis | 1 | 2005 | 16 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2016 | 5 | 0.120 |
Why?
|
| Carcinoma | 1 | 2015 | 22 | 0.110 |
Why?
|
| Epiglottitis | 1 | 1994 | 1 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 75 | 0.110 |
Why?
|
| Mastectomy, Segmental | 2 | 2012 | 21 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 8 | 0.110 |
Why?
|
| Heartburn | 1 | 2014 | 4 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1994 | 10 | 0.110 |
Why?
|
| Kidney Neoplasms | 1 | 1994 | 15 | 0.110 |
Why?
|
| Preconception Care | 2 | 2014 | 40 | 0.110 |
Why?
|
| Liver | 1 | 2014 | 34 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 58 | 0.110 |
Why?
|
| Forearm Injuries | 2 | 2004 | 2 | 0.110 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 11 | 0.110 |
Why?
|
| Tibial Fractures | 2 | 2005 | 2 | 0.110 |
Why?
|
| Leptin | 1 | 2014 | 26 | 0.110 |
Why?
|
| Proteinuria | 1 | 2014 | 25 | 0.110 |
Why?
|
| Anti-Asthmatic Agents | 3 | 2004 | 89 | 0.110 |
Why?
|
| Telephone | 2 | 2014 | 150 | 0.110 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2014 | 21 | 0.110 |
Why?
|
| Foot Injuries | 2 | 2004 | 2 | 0.110 |
Why?
|
| Diabetic Retinopathy | 1 | 2014 | 17 | 0.110 |
Why?
|
| Postnatal Care | 1 | 2014 | 20 | 0.110 |
Why?
|
| Directive Counseling | 1 | 2014 | 23 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 69 | 0.110 |
Why?
|
| Quinolones | 2 | 2010 | 4 | 0.110 |
Why?
|
| Social Identification | 1 | 2013 | 6 | 0.110 |
Why?
|
| Piperazines | 2 | 2010 | 8 | 0.110 |
Why?
|
| Adiposity | 1 | 2014 | 67 | 0.110 |
Why?
|
| Insulin, Long-Acting | 1 | 2013 | 11 | 0.110 |
Why?
|
| Interferons | 1 | 2013 | 5 | 0.100 |
Why?
|
| Liver Function Tests | 1 | 2013 | 6 | 0.100 |
Why?
|
| Ribavirin | 1 | 2013 | 8 | 0.100 |
Why?
|
| Philippines | 2 | 2015 | 25 | 0.100 |
Why?
|
| Financing, Personal | 1 | 2003 | 18 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2014 | 163 | 0.100 |
Why?
|
| Prediabetic State | 1 | 2014 | 52 | 0.100 |
Why?
|
| Chi-Square Distribution | 5 | 2014 | 146 | 0.100 |
Why?
|
| Hospital Costs | 1 | 2013 | 36 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 10 | 0.100 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 8 | 0.100 |
Why?
|
| Office Visits | 1 | 2013 | 73 | 0.100 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2012 | 5 | 0.100 |
Why?
|
| Androstenes | 1 | 2012 | 1 | 0.100 |
Why?
|
| Norgestrel | 1 | 2012 | 1 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 6 | 0.100 |
Why?
|
| Ethinyl Estradiol | 1 | 2012 | 4 | 0.100 |
Why?
|
| Desogestrel | 1 | 2012 | 2 | 0.100 |
Why?
|
| Acute Coronary Syndrome | 1 | 2012 | 17 | 0.100 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 18 | 0.100 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2012 | 1 | 0.100 |
Why?
|
| Genotype | 4 | 2015 | 223 | 0.100 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2012 | 25 | 0.100 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 44 | 0.100 |
Why?
|
| Liver Diseases | 1 | 2012 | 24 | 0.100 |
Why?
|
| Blood Pressure | 4 | 2008 | 275 | 0.100 |
Why?
|
| Diabetic Neuropathies | 1 | 2002 | 10 | 0.100 |
Why?
|
| Vitamin A Deficiency | 1 | 2012 | 3 | 0.090 |
Why?
|
| Breast | 2 | 2010 | 84 | 0.090 |
Why?
|
| Diabetic Nephropathies | 1 | 2002 | 25 | 0.090 |
Why?
|
| Monitoring, Ambulatory | 1 | 2012 | 18 | 0.090 |
Why?
|
| Prepaid Health Plans | 3 | 2006 | 18 | 0.090 |
Why?
|
| Fasting | 5 | 2014 | 46 | 0.090 |
Why?
|
| Blood Pressure Determination | 1 | 2012 | 52 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 52 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 53 | 0.090 |
Why?
|
| Iron | 2 | 2008 | 16 | 0.090 |
Why?
|
| Recurrence | 6 | 2014 | 165 | 0.090 |
Why?
|
| Thinness | 1 | 2011 | 31 | 0.090 |
Why?
|
| Hydrocarbons | 1 | 2011 | 1 | 0.090 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2011 | 3 | 0.090 |
Why?
|
| Diseases in Twins | 4 | 1996 | 15 | 0.090 |
Why?
|
| Fruit | 2 | 2009 | 80 | 0.090 |
Why?
|
| Contrast Media | 1 | 1991 | 9 | 0.090 |
Why?
|
| Vegetables | 2 | 2009 | 88 | 0.090 |
Why?
|
| Angiopoietin-1 | 1 | 2011 | 2 | 0.090 |
Why?
|
| Receptor, TIE-2 | 1 | 2011 | 2 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 3 | 0.090 |
Why?
|
| Angiopoietin-2 | 1 | 2011 | 3 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 5 | 0.090 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 6 | 0.090 |
Why?
|
| Herpes Zoster | 1 | 2012 | 82 | 0.090 |
Why?
|
| Nelfinavir | 1 | 2011 | 4 | 0.090 |
Why?
|
| Schizophrenia, Paranoid | 1 | 2011 | 2 | 0.090 |
Why?
|
| Docosahexaenoic Acids | 1 | 2011 | 7 | 0.090 |
Why?
|
| Molecular Epidemiology | 3 | 2015 | 44 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2011 | 85 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 203 | 0.090 |
Why?
|
| Haplotypes | 4 | 2015 | 34 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 53 | 0.090 |
Why?
|
| Poliovirus Vaccine, Inactivated | 2 | 2001 | 21 | 0.090 |
Why?
|
| Occupational Exposure | 1 | 2011 | 67 | 0.090 |
Why?
|
| Communication | 3 | 2003 | 178 | 0.090 |
Why?
|
| Minority Groups | 1 | 2011 | 104 | 0.090 |
Why?
|
| HIV | 1 | 2010 | 26 | 0.090 |
Why?
|
| Cholesterol, HDL | 2 | 2005 | 69 | 0.090 |
Why?
|
| Outcome Assessment (Health Care) | 3 | 2009 | 215 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2007 | 29 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 15 | 0.080 |
Why?
|
| Referral and Consultation | 3 | 2021 | 157 | 0.080 |
Why?
|
| Access to Information | 1 | 2010 | 12 | 0.080 |
Why?
|
| Alcoholism | 2 | 2012 | 337 | 0.080 |
Why?
|
| Glioma | 1 | 2010 | 4 | 0.080 |
Why?
|
| Carcinoma, Ductal | 1 | 2010 | 4 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 13 | 0.080 |
Why?
|
| Patients | 1 | 2010 | 29 | 0.080 |
Why?
|
| Gastric Acid | 1 | 2010 | 4 | 0.080 |
Why?
|
| Immunization Schedule | 2 | 2001 | 124 | 0.080 |
Why?
|
| Prostatitis | 1 | 2010 | 5 | 0.080 |
Why?
|
| Organophosphonates | 1 | 2010 | 7 | 0.080 |
Why?
|
| Fanconi Syndrome | 1 | 2010 | 5 | 0.080 |
Why?
|
| Adenine | 1 | 2010 | 8 | 0.080 |
Why?
|
| Algorithms | 2 | 2011 | 223 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 4 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 124 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 17 | 0.080 |
Why?
|
| Fetal Macrosomia | 2 | 2006 | 27 | 0.080 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 31 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2010 | 33 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2016 | 31 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 11 | 0.080 |
Why?
|
| Syphilis | 1 | 2010 | 17 | 0.080 |
Why?
|
| Parkinson Disease | 1 | 2009 | 15 | 0.080 |
Why?
|
| Reference Values | 3 | 2015 | 87 | 0.080 |
Why?
|
| Erectile Dysfunction | 1 | 2009 | 24 | 0.080 |
Why?
|
| Suicide, Attempted | 1 | 2010 | 92 | 0.080 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2010 | 54 | 0.080 |
Why?
|
| Mortality | 3 | 2017 | 116 | 0.080 |
Why?
|
| Biopsy | 3 | 2017 | 82 | 0.080 |
Why?
|
| Medicare | 3 | 2019 | 192 | 0.080 |
Why?
|
| Home Care Services | 1 | 2009 | 28 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2009 | 13 | 0.080 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2009 | 6 | 0.080 |
Why?
|
| Gemfibrozil | 1 | 2009 | 5 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 153 | 0.080 |
Why?
|
| Soy Foods | 1 | 2009 | 10 | 0.080 |
Why?
|
| Isoflavones | 1 | 2009 | 14 | 0.080 |
Why?
|
| Suicide | 1 | 2010 | 116 | 0.080 |
Why?
|
| Meat | 1 | 2009 | 27 | 0.080 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 38 | 0.080 |
Why?
|
| San Francisco | 5 | 2011 | 59 | 0.080 |
Why?
|
| Beer | 1 | 2008 | 9 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 6 | 0.080 |
Why?
|
| Somatomedins | 1 | 2008 | 5 | 0.070 |
Why?
|
| Ferritins | 1 | 2008 | 8 | 0.070 |
Why?
|
| Wine | 1 | 2008 | 18 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2006 | 29 | 0.070 |
Why?
|
| Pharmacoepidemiology | 1 | 2008 | 18 | 0.070 |
Why?
|
| Hemochromatosis | 1 | 2008 | 7 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 7 | 0.070 |
Why?
|
| Bayes Theorem | 1 | 2008 | 72 | 0.070 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2008 | 8 | 0.070 |
Why?
|
| Kidney Diseases | 2 | 2011 | 51 | 0.070 |
Why?
|
| Body Fat Distribution | 1 | 2008 | 4 | 0.070 |
Why?
|
| Reproduction | 1 | 2008 | 12 | 0.070 |
Why?
|
| Brain Ischemia | 2 | 1998 | 37 | 0.070 |
Why?
|
| Androgens | 1 | 2008 | 14 | 0.070 |
Why?
|
| Intra-Abdominal Fat | 1 | 2008 | 14 | 0.070 |
Why?
|
| Rectal Neoplasms | 2 | 1995 | 75 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 69 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2008 | 38 | 0.070 |
Why?
|
| Drug Prescriptions | 2 | 2007 | 146 | 0.070 |
Why?
|
| Methylphenidate | 1 | 2007 | 3 | 0.070 |
Why?
|
| Sentinel Surveillance | 1 | 2007 | 12 | 0.070 |
Why?
|
| Environment | 2 | 1999 | 50 | 0.070 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2008 | 46 | 0.070 |
Why?
|
| Reproductive History | 1 | 2007 | 17 | 0.070 |
Why?
|
| Population Surveillance | 2 | 2017 | 252 | 0.070 |
Why?
|
| Twins | 4 | 1996 | 11 | 0.070 |
Why?
|
| Age of Onset | 3 | 2016 | 70 | 0.070 |
Why?
|
| Poisson Distribution | 3 | 2011 | 85 | 0.070 |
Why?
|
| Colonic Polyps | 1 | 2007 | 36 | 0.070 |
Why?
|
| Breast Diseases | 1 | 2007 | 18 | 0.070 |
Why?
|
| Models, Statistical | 2 | 1999 | 170 | 0.070 |
Why?
|
| Cholecystectomy | 1 | 1987 | 2 | 0.070 |
Why?
|
| Abdominal Fat | 1 | 2007 | 13 | 0.070 |
Why?
|
| Prostatic Hyperplasia | 3 | 1992 | 24 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2007 | 26 | 0.070 |
Why?
|
| Functional Laterality | 2 | 2004 | 3 | 0.070 |
Why?
|
| Leisure Activities | 3 | 2006 | 34 | 0.070 |
Why?
|
| Mental Health | 2 | 2024 | 169 | 0.070 |
Why?
|
| Acute Disease | 2 | 2000 | 144 | 0.070 |
Why?
|
| Principal Component Analysis | 3 | 2015 | 24 | 0.070 |
Why?
|
| Homocysteine | 1 | 2007 | 11 | 0.070 |
Why?
|
| Herpesvirus 2, Human | 1 | 2006 | 3 | 0.070 |
Why?
|
| Herpes Simplex | 1 | 2006 | 7 | 0.070 |
Why?
|
| Hyperbilirubinemia | 1 | 2006 | 9 | 0.070 |
Why?
|
| Medical Audit | 3 | 2010 | 32 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2006 | 17 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 114 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 2 | 2004 | 20 | 0.060 |
Why?
|
| Hyperbilirubinemia, Neonatal | 1 | 2006 | 17 | 0.060 |
Why?
|
| Length of Stay | 4 | 2009 | 171 | 0.060 |
Why?
|
| Ulna Fractures | 2 | 2004 | 2 | 0.060 |
Why?
|
| Radius Fractures | 2 | 2004 | 4 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2008 | 185 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2006 | 7 | 0.060 |
Why?
|
| Apolipoproteins E | 1 | 2005 | 9 | 0.060 |
Why?
|
| Pelvis | 1 | 2005 | 2 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2006 | 62 | 0.060 |
Why?
|
| Drug Information Services | 1 | 2005 | 3 | 0.060 |
Why?
|
| Medication Errors | 1 | 2005 | 6 | 0.060 |
Why?
|
| Fibula | 1 | 2005 | 1 | 0.060 |
Why?
|
| Diuretics | 3 | 2008 | 19 | 0.060 |
Why?
|
| Epidemiologic Studies | 2 | 2002 | 29 | 0.060 |
Why?
|
| Environment Design | 1 | 2006 | 67 | 0.060 |
Why?
|
| Warfarin | 1 | 2006 | 72 | 0.060 |
Why?
|
| Antibodies, Protozoan | 1 | 2005 | 3 | 0.060 |
Why?
|
| Toxoplasma | 1 | 2005 | 3 | 0.060 |
Why?
|
| Toxoplasmosis | 1 | 2005 | 4 | 0.060 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2005 | 4 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2005 | 70 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2006 | 125 | 0.060 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 47 | 0.060 |
Why?
|
| Patient Admission | 2 | 2002 | 69 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2006 | 151 | 0.060 |
Why?
|
| Diet Surveys | 2 | 2009 | 56 | 0.060 |
Why?
|
| Remission Induction | 1 | 2014 | 26 | 0.060 |
Why?
|
| Adaptation, Psychological | 2 | 2019 | 78 | 0.060 |
Why?
|
| Prothrombin | 1 | 2004 | 2 | 0.060 |
Why?
|
| Factor V | 1 | 2004 | 5 | 0.060 |
Why?
|
| Utah | 3 | 2014 | 32 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 47 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2024 | 7 | 0.060 |
Why?
|
| Cultural Diversity | 1 | 2004 | 17 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2024 | 16 | 0.050 |
Why?
|
| Sexual Maturation | 1 | 2024 | 8 | 0.050 |
Why?
|
| Central Nervous System Stimulants | 2 | 2007 | 26 | 0.050 |
Why?
|
| Hawaii | 1 | 2024 | 58 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2001 | 47 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2010 | 99 | 0.050 |
Why?
|
| Clinical Competence | 2 | 2004 | 90 | 0.050 |
Why?
|
| Vaccination | 2 | 2016 | 688 | 0.050 |
Why?
|
| Sulfonylurea Compounds | 2 | 2007 | 25 | 0.050 |
Why?
|
| Receptors, Nicotinic | 2 | 2016 | 7 | 0.050 |
Why?
|
| Pelvic Bones | 1 | 2003 | 4 | 0.050 |
Why?
|
| Databases, Factual | 3 | 2010 | 304 | 0.050 |
Why?
|
| Anxiety | 1 | 2024 | 154 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 2 | 2016 | 22 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2003 | 15 | 0.050 |
Why?
|
| Triglycerides | 3 | 2009 | 83 | 0.050 |
Why?
|
| Oxidants, Photochemical | 1 | 2002 | 2 | 0.050 |
Why?
|
| Epidemiologic Methods | 3 | 2009 | 72 | 0.050 |
Why?
|
| Carbon Monoxide | 1 | 2002 | 7 | 0.050 |
Why?
|
| Nitrogen Dioxide | 1 | 2002 | 14 | 0.050 |
Why?
|
| Ozone | 1 | 2002 | 11 | 0.050 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2006 | 22 | 0.050 |
Why?
|
| Myocardial Ischemia | 1 | 2002 | 23 | 0.050 |
Why?
|
| Menstrual Cycle | 1 | 2002 | 5 | 0.050 |
Why?
|
| Ventricular Fibrillation | 1 | 2002 | 4 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2014 | 104 | 0.050 |
Why?
|
| Tachycardia, Ventricular | 1 | 2002 | 5 | 0.050 |
Why?
|
| Oceanic Ancestry Group | 1 | 2012 | 33 | 0.050 |
Why?
|
| Vasectomy | 2 | 1993 | 3 | 0.050 |
Why?
|
| Flatfoot | 1 | 2002 | 1 | 0.050 |
Why?
|
| Diabetic Foot | 1 | 2002 | 3 | 0.050 |
Why?
|
| Bariatric Surgery | 1 | 2014 | 129 | 0.050 |
Why?
|
| Multiphasic Screening | 3 | 2010 | 8 | 0.050 |
Why?
|
| Public Health | 1 | 2003 | 83 | 0.050 |
Why?
|
| Environmental Health | 1 | 2002 | 8 | 0.050 |
Why?
|
| Sigmoidoscopy | 3 | 2007 | 65 | 0.050 |
Why?
|
| Air Pollutants | 1 | 2002 | 54 | 0.050 |
Why?
|
| Direct Service Costs | 2 | 2000 | 8 | 0.050 |
Why?
|
| Diet, Fat-Restricted | 2 | 2014 | 36 | 0.050 |
Why?
|
| China | 2 | 2012 | 132 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 2 | 1998 | 12 | 0.050 |
Why?
|
| Data Collection | 2 | 2007 | 238 | 0.040 |
Why?
|
| Computer Simulation | 2 | 1999 | 80 | 0.040 |
Why?
|
| Anus Neoplasms | 2 | 2012 | 27 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2015 | 16 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2019 | 108 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2004 | 27 | 0.040 |
Why?
|
| Esophagoscopy | 2 | 2013 | 19 | 0.040 |
Why?
|
| Homeostasis | 2 | 2014 | 11 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 9 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 24 | 0.040 |
Why?
|
| Electronic Health Records | 2 | 2017 | 704 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2001 | 142 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2011 | 104 | 0.040 |
Why?
|
| Hypercholesterolemia | 1 | 2000 | 25 | 0.040 |
Why?
|
| Aripiprazole | 2 | 2010 | 5 | 0.040 |
Why?
|
| Ascorbic Acid | 2 | 2011 | 18 | 0.040 |
Why?
|
| Vitamin E | 2 | 2011 | 20 | 0.040 |
Why?
|
| Diagnosis-Related Groups | 1 | 2000 | 19 | 0.040 |
Why?
|
| Bipolar Disorder | 2 | 2010 | 58 | 0.040 |
Why?
|
| Parents | 1 | 2003 | 297 | 0.040 |
Why?
|
| Matched-Pair Analysis | 1 | 2019 | 8 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2000 | 62 | 0.040 |
Why?
|
| Health Facility Environment | 1 | 1999 | 2 | 0.040 |
Why?
|
| Economics, Medical | 1 | 1999 | 4 | 0.040 |
Why?
|
| Accelerometry | 1 | 2019 | 51 | 0.040 |
Why?
|
| Child Health Services | 2 | 2001 | 105 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 76 | 0.040 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2009 | 23 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2009 | 49 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2019 | 19 | 0.040 |
Why?
|
| Occupations | 1 | 1999 | 15 | 0.040 |
Why?
|
| Climacteric | 1 | 1999 | 2 | 0.040 |
Why?
|
| Program Development | 1 | 2019 | 63 | 0.040 |
Why?
|
| Child of Impaired Parents | 2 | 2011 | 27 | 0.040 |
Why?
|
| Deductibles and Coinsurance | 1 | 2009 | 31 | 0.040 |
Why?
|
| Amphetamine | 1 | 1998 | 2 | 0.040 |
Why?
|
| Narcotics | 1 | 1998 | 6 | 0.040 |
Why?
|
| Meditation | 1 | 2019 | 17 | 0.040 |
Why?
|
| Cocaine | 1 | 1998 | 7 | 0.040 |
Why?
|
| Food | 1 | 1998 | 36 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2011 | 17 | 0.040 |
Why?
|
| Hot Flashes | 1 | 1999 | 38 | 0.040 |
Why?
|
| Geography | 2 | 2008 | 39 | 0.040 |
Why?
|
| Levonorgestrel | 1 | 1998 | 5 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2009 | 72 | 0.040 |
Why?
|
| Fertility | 1 | 1998 | 8 | 0.040 |
Why?
|
| Sex Characteristics | 2 | 2015 | 66 | 0.040 |
Why?
|
| Caffeine | 1 | 1998 | 18 | 0.040 |
Why?
|
| Bias | 2 | 2008 | 96 | 0.040 |
Why?
|
| Mastectomy | 1 | 2017 | 35 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2017 | 17 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2007 | 59 | 0.030 |
Why?
|
| Cholesterol, LDL | 2 | 2009 | 112 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 1997 | 48 | 0.030 |
Why?
|
| Nurse-Patient Relations | 1 | 1997 | 8 | 0.030 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2007 | 97 | 0.030 |
Why?
|
| Mothers | 1 | 2018 | 103 | 0.030 |
Why?
|
| Premenopause | 1 | 2017 | 24 | 0.030 |
Why?
|
| Twins, Monozygotic | 3 | 1993 | 11 | 0.030 |
Why?
|
| Diphosphonates | 1 | 2017 | 63 | 0.030 |
Why?
|
| Hospitals | 1 | 1997 | 71 | 0.030 |
Why?
|
| Serogroup | 1 | 2016 | 10 | 0.030 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2016 | 8 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2016 | 21 | 0.030 |
Why?
|
| Calcium Oxalate | 1 | 1996 | 2 | 0.030 |
Why?
|
| Diet, Protein-Restricted | 1 | 1996 | 2 | 0.030 |
Why?
|
| Self Care | 1 | 2007 | 144 | 0.030 |
Why?
|
| Kidney Calculi | 1 | 1996 | 6 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 2016 | 59 | 0.030 |
Why?
|
| Animals | 2 | 2009 | 280 | 0.030 |
Why?
|
| Acyclovir | 1 | 1996 | 5 | 0.030 |
Why?
|
| Facial Paralysis | 1 | 1996 | 2 | 0.030 |
Why?
|
| Prednisone | 1 | 1996 | 6 | 0.030 |
Why?
|
| Goals | 1 | 2016 | 27 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 5 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 32 | 0.030 |
Why?
|
| Heart Valve Diseases | 1 | 2016 | 17 | 0.030 |
Why?
|
| Washington | 2 | 2012 | 384 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 2 | 2006 | 19 | 0.030 |
Why?
|
| Genes, Modifier | 1 | 2016 | 2 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2016 | 71 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 13 | 0.030 |
Why?
|
| Indians, North American | 1 | 2016 | 48 | 0.030 |
Why?
|
| Larynx | 1 | 1995 | 1 | 0.030 |
Why?
|
| Mouth | 1 | 1995 | 1 | 0.030 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 1995 | 1 | 0.030 |
Why?
|
| Paranasal Sinuses | 1 | 1995 | 1 | 0.030 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1995 | 2 | 0.030 |
Why?
|
| Pharynx | 1 | 1995 | 3 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 1995 | 2 | 0.030 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2011 | 22 | 0.030 |
Why?
|
| Mouth Neoplasms | 1 | 1995 | 9 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 8 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2015 | 7 | 0.030 |
Why?
|
| Bereavement | 1 | 1995 | 5 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 25 | 0.030 |
Why?
|
| Osmolar Concentration | 2 | 1993 | 8 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 41 | 0.030 |
Why?
|
| Abdomen | 1 | 2005 | 20 | 0.030 |
Why?
|
| Self Disclosure | 1 | 1995 | 19 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 85 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2015 | 19 | 0.030 |
Why?
|
| Pedigree | 1 | 2015 | 63 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 38 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 80 | 0.030 |
Why?
|
| Phylogeny | 1 | 2015 | 15 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 18 | 0.030 |
Why?
|
| Urinalysis | 1 | 1995 | 9 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2016 | 149 | 0.030 |
Why?
|
| Tracheotomy | 1 | 1994 | 2 | 0.030 |
Why?
|
| Social Environment | 1 | 1995 | 85 | 0.030 |
Why?
|
| Palpation | 2 | 1991 | 10 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 1994 | 6 | 0.030 |
Why?
|
| Citrus | 1 | 2014 | 3 | 0.030 |
Why?
|
| Lycopersicon esculentum | 1 | 2014 | 4 | 0.030 |
Why?
|
| Tea | 1 | 2014 | 8 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2014 | 5 | 0.030 |
Why?
|
| Calcium, Dietary | 2 | 2004 | 28 | 0.030 |
Why?
|
| Hydrochlorothiazide | 1 | 1994 | 4 | 0.030 |
Why?
|
| Carbonated Beverages | 1 | 2014 | 15 | 0.030 |
Why?
|
| Michigan | 2 | 2006 | 28 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 7 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 9 | 0.030 |
Why?
|
| Trastuzumab | 1 | 2014 | 19 | 0.030 |
Why?
|
| Lipoprotein(a) | 1 | 1994 | 5 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 55 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2014 | 12 | 0.030 |
Why?
|
| Absorptiometry, Photon | 2 | 2008 | 51 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2014 | 13 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 45 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 29 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 1994 | 86 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 36 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 1993 | 8 | 0.030 |
Why?
|
| Insulin Glargine | 1 | 2013 | 8 | 0.030 |
Why?
|
| Eating | 1 | 1993 | 34 | 0.030 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2003 | 5 | 0.030 |
Why?
|
| Administration, Inhalation | 2 | 2004 | 40 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 19 | 0.030 |
Why?
|
| Psychometrics | 1 | 2013 | 119 | 0.030 |
Why?
|
| Necrosis | 1 | 2012 | 3 | 0.030 |
Why?
|
| Health Education | 1 | 2003 | 82 | 0.020 |
Why?
|
| Tennessee | 1 | 2012 | 6 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 9 | 0.020 |
Why?
|
| Arteries | 1 | 2012 | 8 | 0.020 |
Why?
|
| Twins, Dizygotic | 2 | 1990 | 7 | 0.020 |
Why?
|
| Social Networking | 1 | 2012 | 19 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 43 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2012 | 32 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2012 | 57 | 0.020 |
Why?
|
| Amputation | 1 | 2002 | 11 | 0.020 |
Why?
|
| Environmental Exposure | 2 | 2009 | 121 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2012 | 26 | 0.020 |
Why?
|
| International Cooperation | 1 | 2012 | 15 | 0.020 |
Why?
|
| Infant Food | 1 | 2011 | 7 | 0.020 |
Why?
|
| Virus Replication | 1 | 2011 | 13 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2012 | 131 | 0.020 |
Why?
|
| Bottle Feeding | 1 | 2011 | 7 | 0.020 |
Why?
|
| Far East | 1 | 2011 | 6 | 0.020 |
Why?
|
| Carotenoids | 1 | 2011 | 28 | 0.020 |
Why?
|
| Cost Control | 1 | 1991 | 13 | 0.020 |
Why?
|
| Genome, Human | 1 | 2011 | 34 | 0.020 |
Why?
|
| Pediatrics | 2 | 2004 | 142 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2011 | 2 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 5 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2011 | 4 | 0.020 |
Why?
|
| Panic Disorder | 1 | 2010 | 5 | 0.020 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2010 | 25 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 151 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2010 | 3 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2010 | 12 | 0.020 |
Why?
|
| Pathology, Clinical | 1 | 2010 | 14 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2010 | 26 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2010 | 30 | 0.020 |
Why?
|
| Laboratories | 1 | 2010 | 19 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 18 | 0.020 |
Why?
|
| Blood Proteins | 1 | 1990 | 4 | 0.020 |
Why?
|
| Phenotype | 2 | 2005 | 149 | 0.020 |
Why?
|
| Drug Utilization | 2 | 2004 | 121 | 0.020 |
Why?
|
| Uric Acid | 1 | 1990 | 9 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2010 | 19 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 1990 | 32 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2010 | 8 | 0.020 |
Why?
|
| Diet Records | 1 | 2010 | 37 | 0.020 |
Why?
|
| Heart Rate | 1 | 1990 | 38 | 0.020 |
Why?
|
| Massachusetts | 1 | 2010 | 60 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 3 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 22 | 0.020 |
Why?
|
| Carcinogenicity Tests | 1 | 2009 | 2 | 0.020 |
Why?
|
| Carcinogens | 1 | 2009 | 3 | 0.020 |
Why?
|
| Tenofovir | 1 | 2010 | 18 | 0.020 |
Why?
|
| Obesity, Morbid | 1 | 2011 | 119 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 31 | 0.020 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1989 | 3 | 0.020 |
Why?
|
| Sunlight | 1 | 2009 | 13 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 1989 | 7 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2010 | 45 | 0.020 |
Why?
|
| Sarcoma, Kaposi | 1 | 1989 | 12 | 0.020 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2009 | 18 | 0.020 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2009 | 27 | 0.020 |
Why?
|
| Thiazoles | 1 | 2009 | 10 | 0.020 |
Why?
|
| Creatinine | 1 | 2010 | 66 | 0.020 |
Why?
|
| Patient Discharge | 2 | 2005 | 153 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2010 | 100 | 0.020 |
Why?
|
| Clozapine | 1 | 2009 | 6 | 0.020 |
Why?
|
| Dietary Sucrose | 1 | 2009 | 13 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2009 | 28 | 0.020 |
Why?
|
| Occupational Health Services | 1 | 2009 | 12 | 0.020 |
Why?
|
| Workplace | 1 | 2009 | 29 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 28 | 0.020 |
Why?
|
| Small-Area Analysis | 1 | 2009 | 4 | 0.020 |
Why?
|
| Trans Fatty Acids | 1 | 2009 | 4 | 0.020 |
Why?
|
| Cooking | 1 | 2009 | 17 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 4 | 0.020 |
Why?
|
| DNA Ligase ATP | 1 | 2008 | 2 | 0.020 |
Why?
|
| DNA Ligases | 1 | 2008 | 2 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2008 | 2 | 0.020 |
Why?
|
| Endonucleases | 1 | 2008 | 3 | 0.020 |
Why?
|
| Computer-Assisted Instruction | 1 | 2008 | 10 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 11 | 0.020 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2009 | 21 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2008 | 3 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 8 | 0.020 |
Why?
|
| Iron, Dietary | 1 | 2008 | 8 | 0.020 |
Why?
|
| Outpatients | 1 | 2009 | 101 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2008 | 14 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 13 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2008 | 19 | 0.020 |
Why?
|
| Ligands | 1 | 2008 | 6 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 30 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2010 | 155 | 0.020 |
Why?
|
| Antiprotozoal Agents | 1 | 2008 | 2 | 0.020 |
Why?
|
| Griseofulvin | 1 | 2008 | 2 | 0.020 |
Why?
|
| Metronidazole | 1 | 2008 | 4 | 0.020 |
Why?
|
| Furosemide | 1 | 2008 | 3 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2008 | 4 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 81 | 0.020 |
Why?
|
| Sodium, Dietary | 1 | 1988 | 10 | 0.020 |
Why?
|
| beta Carotene | 1 | 2008 | 17 | 0.020 |
Why?
|
| Hemochromatosis Protein | 1 | 2008 | 7 | 0.020 |
Why?
|
| Homozygote | 1 | 2008 | 13 | 0.020 |
Why?
|
| Heterozygote | 1 | 2008 | 26 | 0.020 |
Why?
|
| Virilism | 1 | 2008 | 2 | 0.020 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2008 | 3 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2008 | 13 | 0.020 |
Why?
|
| Lovastatin | 1 | 2008 | 7 | 0.020 |
Why?
|
| Amphetamines | 1 | 2007 | 2 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 1 | 2007 | 2 | 0.020 |
Why?
|
| Pemoline | 1 | 2007 | 2 | 0.020 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2007 | 10 | 0.020 |
Why?
|
| Simvastatin | 1 | 2008 | 11 | 0.020 |
Why?
|
| Men's Health | 1 | 2007 | 20 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2007 | 8 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2007 | 13 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2007 | 33 | 0.020 |
Why?
|
| Demography | 1 | 2007 | 93 | 0.020 |
Why?
|
| Thigh | 1 | 2007 | 11 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2007 | 23 | 0.020 |
Why?
|
| Weaning | 1 | 2007 | 3 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 64 | 0.020 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2007 | 4 | 0.020 |
Why?
|
| Information Systems | 2 | 1997 | 14 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2007 | 31 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2007 | 17 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2007 | 48 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2007 | 13 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 14 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 2006 | 8 | 0.020 |
Why?
|
| Tetracyclines | 1 | 2006 | 2 | 0.020 |
Why?
|
| Rosacea | 1 | 2006 | 3 | 0.020 |
Why?
|
| Macrolides | 1 | 2006 | 6 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 42 | 0.020 |
Why?
|
| Acne Vulgaris | 1 | 2006 | 8 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2006 | 33 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2006 | 66 | 0.020 |
Why?
|
| Capecitabine | 1 | 2006 | 2 | 0.020 |
Why?
|
| Contraindications | 1 | 2006 | 14 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2006 | 11 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2006 | 106 | 0.010 |
Why?
|
| Walking | 1 | 2006 | 89 | 0.010 |
Why?
|
| Emergency Service, Hospital | 2 | 1999 | 384 | 0.010 |
Why?
|
| Syndrome | 2 | 1996 | 28 | 0.010 |
Why?
|
| Accident Prevention | 1 | 2004 | 2 | 0.010 |
Why?
|
| Benzothiadiazines | 1 | 2004 | 2 | 0.010 |
Why?
|
| Behavior | 1 | 2004 | 17 | 0.010 |
Why?
|
| Posture | 1 | 2004 | 4 | 0.010 |
Why?
|
| State Health Plans | 1 | 2004 | 32 | 0.010 |
Why?
|
| Vision Disorders | 1 | 2004 | 15 | 0.010 |
Why?
|
| Family Practice | 1 | 2004 | 40 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 2004 | 5 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2004 | 33 | 0.010 |
Why?
|
| Humeral Fractures | 1 | 2003 | 2 | 0.010 |
Why?
|
| Religion | 1 | 2003 | 17 | 0.010 |
Why?
|
| Particle Size | 1 | 2002 | 5 | 0.010 |
Why?
|
| Vehicle Emissions | 1 | 2002 | 23 | 0.010 |
Why?
|
| Amiodarone | 1 | 2002 | 2 | 0.010 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2002 | 13 | 0.010 |
Why?
|
| Heart Arrest | 1 | 2002 | 33 | 0.010 |
Why?
|
| Statistics as Topic | 2 | 1993 | 56 | 0.010 |
Why?
|
| Defibrillators, Implantable | 1 | 2002 | 32 | 0.010 |
Why?
|
| Employment | 1 | 2002 | 44 | 0.010 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2001 | 3 | 0.010 |
Why?
|
| Immunity | 1 | 2001 | 6 | 0.010 |
Why?
|
| Quality Indicators, Health Care | 1 | 2002 | 125 | 0.010 |
Why?
|
| Poverty | 1 | 2002 | 168 | 0.010 |
Why?
|
| Consumer Behavior | 1 | 2001 | 28 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 2000 | 13 | 0.010 |
Why?
|
| Models, Econometric | 1 | 2000 | 9 | 0.010 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2001 | 88 | 0.010 |
Why?
|
| Health Policy | 1 | 2001 | 109 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1999 | 4 | 0.010 |
Why?
|
| Trust | 1 | 1999 | 32 | 0.010 |
Why?
|
| Body Height | 1 | 1999 | 60 | 0.010 |
Why?
|
| Minnesota | 1 | 1998 | 51 | 0.010 |
Why?
|
| Progesterone Congeners | 1 | 1998 | 5 | 0.010 |
Why?
|
| Cocaine-Related Disorders | 1 | 1998 | 5 | 0.010 |
Why?
|
| Medical History Taking | 1 | 1998 | 33 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2001 | 310 | 0.010 |
Why?
|
| Drug Implants | 1 | 1998 | 2 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1998 | 6 | 0.010 |
Why?
|
| Urban Population | 1 | 1998 | 109 | 0.010 |
Why?
|
| Cerebral Infarction | 1 | 1998 | 6 | 0.010 |
Why?
|
| Beverages | 1 | 1998 | 18 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1999 | 131 | 0.010 |
Why?
|
| Ischemic Attack, Transient | 1 | 1998 | 27 | 0.010 |
Why?
|
| Laundering | 1 | 1997 | 2 | 0.010 |
Why?
|
| Bedding and Linens | 1 | 1997 | 4 | 0.010 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1997 | 10 | 0.010 |
Why?
|
| Writing | 1 | 1997 | 11 | 0.010 |
Why?
|
| Health Priorities | 1 | 1997 | 24 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1997 | 45 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 226 | 0.010 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 1997 | 12 | 0.010 |
Why?
|
| Family | 1 | 1998 | 106 | 0.010 |
Why?
|
| Cohort Effect | 1 | 1996 | 3 | 0.010 |
Why?
|
| Sampling Studies | 1 | 1996 | 43 | 0.010 |
Why?
|
| Fluid Therapy | 1 | 1996 | 10 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1996 | 2 | 0.010 |
Why?
|
| Intensive Care, Neonatal | 1 | 1996 | 4 | 0.010 |
Why?
|
| Death Certificates | 1 | 1996 | 17 | 0.010 |
Why?
|
| Infant Mortality | 1 | 1996 | 15 | 0.010 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 1996 | 38 | 0.010 |
Why?
|
| Physical Examination | 1 | 1995 | 19 | 0.010 |
Why?
|
| Hematuria | 1 | 1995 | 7 | 0.010 |
Why?
|
| Glucose | 1 | 1993 | 31 | 0.010 |
Why?
|
| Insurance, Major Medical | 1 | 1992 | 1 | 0.010 |
Why?
|
| Random Allocation | 1 | 1992 | 33 | 0.010 |
Why?
|
| Reoperation | 1 | 1992 | 23 | 0.010 |
Why?
|
| Selection Bias | 1 | 1991 | 16 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1991 | 28 | 0.010 |
Why?
|
| Rectum | 1 | 1991 | 13 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1990 | 12 | 0.010 |
Why?
|
| Group Practice, Prepaid | 1 | 1990 | 6 | 0.010 |
Why?
|
| Life Tables | 1 | 1990 | 7 | 0.010 |
Why?
|
| Computer Systems | 1 | 1988 | 2 | 0.000 |
Why?
|